Moxonidine for the treatment of fibromyalgia: a prospective double-blind, randomised, single-centre, placebo-controlled, parallel group study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN70535562

Enrollment

Registered

2005-11-07

Start date

2005-12-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia Musculoskeletal Diseases Fibromyalgia

Interventions

1. Moxonidine 0.2 mg/12 hours 2. Placebo/12 hours

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Ages eligible for study: 30 - 60 years 2. Genders eligible for study: both 3. Diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) criteria

Exclusion criteria

Exclusion criteria: 1. Psychiatric illness 2. Depression 3. Suicidal risk 4. Substance abuse 5. Pulmonary dysfunction 6. Renal impairment 7. Active cardiac disease 8. Liver disease 9. Autoimmune disease 10. Cancer 11. Sleep apnea 12. Chronic Fatigue Syndrome 13. Inflammatory bowel disease 14. Contraindication of Moxonidine

Design outcomes

Primary

Measure	Time frame
The primary outcome was improvement in the pain score (10-cm visual analog scale [VAS]) at 24 weeks.	—

Secondary

Measure	Time frame
1. Fibromyalgia Impact Questionnaire (FIQ) 2. The tender point score 3. The Hamilton Anxiety and Depression Scale (HADS)	—

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026